At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 584 enrolled
Drug / intervention
liraglutide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.
In Brief
A Phase 3 clinical trial evaluating liraglutide, insulin glargine, and 2 other interventions for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 584 participants across 116 sites in 18 countries.
Detailed Summary
This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Austria, Brazil, Denmark, Finland, France, India, Italy, Netherlands, Norway, Philippines, Poland, Russia, Serbia and Montenegro, Slovakia, South Africa, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMay 2006
Primary CompletionApr 2007
TodayJul 2026
First PostedMay 31, 2006
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.1 years ago
Interventions
liraglutidedrug
insulin glarginedrug
metformindrug
glimepiridedrug